New Investigators. We are requesting $150,000 per year to support 2-3 new investigators for one to three years for start-up of their research. The recruitments occur in partnership with Departments, and can be initiated by either partner. The funds are intended to guarantee technical support and supplies for junior-level investigators. However, it is possible that these funds could be combined into a larger package for a more senior individual. The University of Virginia will pay for the salary and most of the equipment costs of these recruits, and in addition the Cancer Center has available $500,000 per year from the School of Medicine to aid in recruitment. Further matching almost invariably is obtained from the Department that we partner with in these recruitments. Thus, funds from the CCSG permit the Cancer Center to leverage a relatively modest investment into a considerable influence on the future of the University of Virginia Health Sciences Center. As described in Section 6.3, our focus for recruitments during the next funding period will be to bolster clinical investigations, strengthen cancer-focused basic and translational research, and strengthen Cancer Control. Clinical investigators will be chosen who will work well within our collaborative environment, and who have an interest and expertise in molecularly targeted therapies, biomarkers, and imaging, especially in the major solid tumors. Translational investigators will be recruited to help development of translational working groups, especially in the areas of immunotherapy, women's oncology, prostate cancer, and aerodigestive cancers. In addition, we will look for opportunities to partner with basic science departments, to recruit outstanding cancer-focused basic scientists, with the Departments of Biomedical Engineering and Radiology to bolster our capability in cancer imaging, and with the Department of Public Health Sciences, to strengthen the foundation for movement toward Comprehensive status.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-19
Application #
7771650
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
19
Fiscal Year
2009
Total Cost
$102,729
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148
Carlton, Anne L; Illendula, Anuradha; Gao, Yan et al. (2018) Small molecule inhibition of the CBF?/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition. Gynecol Oncol 149:350-360
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562

Showing the most recent 10 out of 539 publications